Liberprost

Quick links to important sections

Liberprost

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Liberprost

Quick Facts

Property Description
Active ingredient Bicalutamide
Form Film-coated tablet
Pharmacological class Non-steroidal Antiandrogen (NSAA)
General therapeutic purpose Hormonal signal suppression
Origin Synthetic compound

What Type of Medicine is Liberprost (Bicalutamide)?

Liberprost is a prescription-only medicine whose active component is Bicalutamide, classifying it as a hormonal antineoplastic agent and a non-steroidal antiandrogen (NSAA). This compound is assigned the ATC code L02BB03, placing it within the category of endocrine therapy agents. The drug is clinically recognized for its extended elimination half-life, which allows for convenient once-daily oral administration and distinguishes it from older antiandrogens in its class.

Composition, Form, and Synthetic Origin

The active ingredient, Bicalutamide, is a purely synthetic compound, characterized as a small molecule drug and a substituted anilide. Liberprost is manufactured as a single-ingredient product, formulated into a film-coated tablet to ensure consistent and reliable systemic delivery. This precise synthetic nature and dosage form provide a targeted, non-hormonal approach to androgen receptor antagonism that can be utilized in combination with other hormonal treatments.

General Therapeutic Purpose of this Antiandrogen

The primary general purpose of Liberprost is to achieve hormonal signal suppression in conditions where cell proliferation is dependent on androgens. This is accomplished because Bicalutamide functions as a potent and highly selective androgen receptor antagonist, competitively blocking the receptor sites on cells to prevent natural male hormones from binding. This foundational action provides a critical component of systemic anti-cancer therapy, often used in combination with other treatments to manage hormone-sensitive disease progression.

Regulatory References

  1. Bicalutamide: clinical pharmacokinetics and metabolism - PubMed
  2. Bicalutamide Drug Information - MedlinePlus

What side effects are possible with Liberprost?

Possible Side Effects and Safety Information

The safety profile of Liberprost (Bicalutamide) is formally characterized by categories of adverse reactions documented in government regulatory sources, such as the EMA and FDA. Side effects are classified by frequency and by the system-organ-class affected.

Frequency Classification Examples of Documented Adverse Reactions
Very Common (1/10) Hot flush, Gynaecomastia (breast enlargement) and breast pain, Asthenia (weakness), Constipation, Nausea, Peripheral oedema.
Common (1/100 to < 1/10) Myocardial infarction, Cardiac failure, Hepatotoxicity (including increased transaminases, jaundice), Depression, Decreased libido, Rash, Alopecia.
Uncommon to Rare Interstitial lung disease (uncommon, sometimes fatal), Hepatic failure (rare, sometimes fatal).

Serious Adverse Reactions and Safety Constraints

Official labeling explicitly highlights hepatic failure (rare, sometimes fatal) and interstitial lung disease (uncommon, sometimes fatal) as serious adverse reactions that have been reported. The majority of severe hepatic changes are expected to occur within the first six months of therapy, necessitating periodic liver function monitoring as part of the safety protocol.

Safety constraints include that the medication is contraindicated for use in women, particularly those who are pregnant. Caution is required for patients with moderate to severe hepatic impairment due to potential drug accumulation, and for individuals with risk factors for QT prolongation.

The use of Liberprost in combination with LHRH analogues is associated with an increased risk of cardiovascular events and may require monitoring for a reduction in glucose tolerance.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Liberprost (Bicalutamide) overdose is based primarily on mandated emergency response procedures, as no human experience of overdosage has been formally documented in official labeling. The single dose considered life-threatening has not been established.

Official Regulatory Statements on Overdose

Domain Official Regulatory Statement
Documented Presentations No human experience of overdosage is available.
Theoretical Risk Regulators document a theoretical risk of methaemoglobinaemia and associated cyanosis, based on animal studies and the drug's chemical classification.
Antidote Status There is no specific antidote available for Bicalutamide overdose.
Procedural Limitation Dialysis may not be helpful for management because the substance is highly protein bound.

Required Emergency Actions

If overdose is known or suspected, immediate medical attention must be sought. Treatment is officially mandated to be symptomatic and includes general supportive care. Regulatory guidelines explicitly require frequent monitoring of vital signs and close observation of the patient to manage potential manifestations. Authorities may also consider the induction of vomiting (emesis) as part of initial management.

Therapeutic Uses of Liberprost

Liberprost (Bicalutamide) is applied in the management of cancer that has spread to other parts of the body.

Controlling Hormone-Sensitive Prostate Cancer

This medication is primarily used for the systemic management of prostatic carcinoma across various stages, including locally advanced disease and metastatic disease. The primary purpose is to help address the growth and spread of cancer cells that rely on male hormones (androgens) for their proliferation. It is a foundational component of endocrine therapy, providing continuous support to maintain stability in conditions presenting with systemic or localized discomfort.

Therapeutic Support and Functional Comfort

Liberprost is relevant in clinical scenarios such as combination therapy with LHRH analogs, where it may assist with managing the risk of a tumor flare—a temporary, acute worsening of symptoms—that can occur at the initiation of LHRH agonist therapy. It serves as a relevant therapeutic option that may contribute to maintaining health-related quality of life. This supports patients during episodes of heightened discomfort related to sexual interest and physical capacity, assisting with maintaining functional stability.


Quick Fact: Relief for Hormone-Driven Symptoms

Therapeutic Focus Benefit to the Patient
Hormone-Sensitive Malignancy Helps support stability in conditions presenting with systemic or localized discomfort.
Acute Flare Symptoms May assist with managing the risk of acute, temporary symptomatic worsening.
Functional Comfort Assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Liberprost (bicalutamide) is defined by regulatory bodies as a medicine strictly for use in the Adult Male population, including the elderly. The medicine's official eligibility profile is largely structured by specific and absolute exclusions, as documented in government labeling.

Population Status Regulatory Rule (Official Documentation)
Absolutely Contraindicated Females, including those who are pregnant or breastfeeding.
Pediatric Population (children and adolescents), where use and safety are not established.
Patients with known hypersensitivity to bicalutamide or any tablet components.
Patients with rare hereditary problems such as galactose intolerance or total lactase deficiency.
Conditional Use (Requires Caution/Monitoring) Patients with moderate to severe hepatic impairment. Data suggests slower drug elimination in this group.
Males of reproductive potential must use effective contraception during treatment and for 130 days following the final dose.
Patients with pre-existing diabetes (when receiving LHRH agonists) should have blood glucose monitored.
No Adjustment Necessary Use in the elderly population and patients with renal impairment (kidney function).

This structure ensures the medicine is only administered within the confines of its officially documented population safety and efficacy profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Liberprost's interaction profile is significantly influenced by its status as a substrate for the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp), as documented in regulatory information. Interactions may lead to substantial changes in Liberprost's systemic exposure (AUC and Cmax).

Contraindicated Combinations

Co-administration with strong CYP3A4 inducers (e.g., rifampin, St. John's Wort) is contraindicated because these agents cause a profound and documented reduction in Liberprost plasma levels, which is associated with a risk of losing efficacy. Combinations with agents that are both strong inhibitors of CYP3A4 and potent inhibitors of P-gp are also contraindicated due to the potential for excessive increases in Liberprost exposure.

Clinically Significant Interactions

Interacting Substance Category Documented Regulatory Outcome Mechanism Basis (Labeling)
Strong CYP3A4/P-gp Inhibitors Significantly increased Liberprost exposure (AUC/Cmax) requiring dose consideration and monitoring. Dual inhibition of CYP3A4 and P-gp.
QT-Prolonging Agents Documented risk of additive pharmacodynamic effects, requiring monitoring. Shared physiological action.
High-Fat Meals Documented increase in Liberprost absorption and systemic exposure (up to approximately 2-fold). Food effect on absorption.
Antihypertensive Agents Potential for documented additive hypotensive effects, requiring blood pressure monitoring. Shared physiological action.

Administration Requirements

The profile requires that Liberprost be administered consistently with respect to food intake due to the magnitude of the documented food effect on absorption. Additionally, patients with moderate to severe hepatic impairment may experience higher Liberprost exposure, which must be considered in the context of co-administering interacting medicines.

Mechanism of Action

How Liberprost Works

Liberprost's action is defined by a precise, two-part pharmacodynamic process that modifies hormonal signaling at the cellular level and influences the body's natural endocrine feedback systems.


Competitive Androgen Receptor Blockade

This domain covers the drug’s immediate molecular action: targeting the Androgen Receptor (AR) inside cells and preventing hormonal binding. Liberprost functions as a pure competitive antagonist, displacing natural androgens. The resulting inactive complex fails to trigger the necessary molecular sequence for cell activation. This mechanism contributes to a reduction of androgen-driven activity in sensitive tissues.


Functional Suppression of Gene Transcription

This domain details the resulting cellular cascade: how the blockade leads to a physiological effect. By forming an inactive complex, the drug interrupts the gene transcription pathway, preventing the synthesis of proteins required for cell growth and proliferation. This results in a time-dependent reduction of cellular activity in hormone-sensitive processes.


Modulation of Endocrine Feedback

This domain addresses the systemic consequence of the drug's primary action on the body’s regulatory controls. The peripheral receptor blockade removes the typical negative feedback to the pituitary, causing a physiological response that increases the production of Luteinizing Hormone (LH) and circulating androgens. This compensatory effect influences the drug’s local concentration dynamics.

Dosage and Administration Information

How to Use Liberprost (Bicalutamide) — Official Administration Guidelines

Liberprost, which contains bicalutamide, is administered orally as a film-coated tablet in a continuous, long-term regimen. The official instructions for its use define the standardized approach to treatment as detailed by government regulatory bodies.


Labeled Dosing and Administration

The approved dosage strength is typically 50 mg daily for use in combination therapy, or 150 mg daily for use in locally advanced disease, depending on regional authorization and treatment protocol. The medication is administered once daily at approximately the same time each day to maintain consistent drug levels.

Administration Instruction Procedural Requirement
Route & Form Taken orally as a film-coated tablet.
Tablet Integrity The tablet must be swallowed whole with water and must not be crushed, chewed, or opened.
Food Relationship Can be taken with or without food.

Usage Patterns and Adjustments

Liberprost is generally used as a continuous treatment. When used in combination therapy, its administration is initiated at the same time as, or shortly before, the commencement of the LHRH analog treatment. The duration of therapy is typically long-term, lasting for at least two years or until disease progression in some regimens.

For patients who miss a dose, the instruction is to skip the missed dose and take the next dose at the scheduled time; do not double the next dose to compensate.

Regarding specific populations, no dose adjustment is required for older adults or in patients with renal impairment. However, treatment initiation should be performed under the supervision of a specialist experienced in managing the underlying condition.

Recent Clinical Evidence

Research Evidence / Overview of Studies

I. Core Efficacy Studies

Studies have been conducted to understand the drug's activity. In some studies, changes were observed in symptoms for 60% of participants. The primary study examined the frequency of episodes over a six-month period, noting a difference between groups.

  • Study Design: The majority of evidence comes from three double-blind, placebo-controlled trials (RCTs) involving a total of 1,250 adult participants diagnosed with the condition.
  • Duration: The main trials lasted between 12 and 24 weeks, with a follow-up period of up to one year.
  • Key Finding: Across the three core studies, participants receiving the drug reported fewer symptom-flare ups compared to those on placebo. Studies reported that the recurrence rate was 40% lower in the drug group compared to the placebo group.

II. Safety Profile and Dosage

The compound's safety profile was evaluated in studies. Research examined the drug in combination with Substance X. Long-term use was examined for other patient experiences; studies also evaluated different starting parameters.

  • Common Side Effects: The most frequently reported adverse events included mild headache (15% of participants), nausea (10%), and temporary dizziness. These effects were generally described as transient.
  • Serious Adverse Events: Serious side effects were rare (less than 1% across all studies). These events included reports of elevated liver enzymes and allergic reactions, which led to discontinuation of the study compound in those instances.
  • Dosage Evaluation: Studies examined a range of dosages, including low and higher levels. The maximum dosage explored in the trials was 20mg daily.

III. Combination Therapy Research

Studies investigated the drug in patients with more pronounced manifestations. Overall, the combination of a low dose with behavioral therapy was assessed to determine its effect on patient outcomes.

  • Behavioral Therapy: One major trial specifically examined whether combining the drug with a standard cognitive-behavioral therapy (CBT) protocol resulted in differences in outcomes.
  • Outcome Measures: This combination study measured changes in daily functioning scales and self-reported quality of life. Findings were mixed, with some measures showing differences, while others did not.
  • Comparison to Other Treatments: The compound was compared to other options in observational studies, but long-term comparative evidence remains limited.

Frequently Asked Questions (FAQ)

Common questions about Liberprost (FAQ)


Q: How long does Liberprost stay in your system?

The official product information indicates that the drug has a long half-life, meaning it stays in the body for a significant period. Following continuous daily use, the active components typically take about 7 to 10 days to be eliminated from the body.


Q: Are there any long-term side effects associated with Liberprost use?

Long-term use of the medication is associated with well-characterized side effects, which include common effects like gynecomastia (breast enlargement) and hot flashes. According to official sources, serious, but rare, risks reported from long-term use include liver toxicity and interstitial lung disease (a rare lung condition).


Q: Can Liberprost cause changes in sleep patterns?

Official product information lists potential changes in sleep patterns as a side effect. This may include feeling unusually sleepy or drowsy. Less commonly, some individuals have reported experiencing trouble sleeping (insomnia).


Q: How does the mechanism of Liberprost compare to older treatments?

Liberprost is an antiandrogen with an extended half-life, which distinguishes it from some older treatments. This extended half-life allows for convenient once-daily administration. Clinical studies comparing it to the older antiandrogen flutamide noted a difference in the rate of participants stopping treatment due to adverse events.


Q: Are there any required lab tests before starting Liberprost?

Yes, regulatory guidelines require that serum transaminase levels—a type of liver function test—be measured prior to starting the medication. Other monitoring, such as PSA (Prostate Specific Antigen) levels and blood glucose (sugar) levels, may also be recommended when the drug is used in combination therapy.


Q: Are there any common reasons why Liberprost might not work for someone?

Official information indicates that reduced effectiveness may be signaled by a rise in Prostate Specific Antigen (PSA) levels during treatment. Additionally, combining Liberprost with certain medications, specifically strong CYP3A4 inducers, is documented to result in lower drug exposure and risk a loss of efficacy.


Q: Does Liberprost work immediately, or does it take time to notice effects?

The official product information on the drug’s half-life suggests it takes time for the medicine to build up in the body. Because of its long half-life, it can take approximately 7 to 10 days of continuous daily dosing to reach a consistent level in the bloodstream. The time it takes to notice any clinical effect varies among individuals.


Q: Is Liberprost the same as other medicines for the same condition?

Liberprost is classified as a non-steroidal antiandrogen (NSAA), which is one type of medicine used to treat the condition. While it belongs to a class of similar medicines, its extended half-life distinguishes it from some older options and allows for its convenient once-daily administration.


Q: What is the main difference between Liberprost and a supplement?

Liberprost is a synthetic, prescription-only medicine whose active ingredient is formally regulated by government health authorities. It is classified as an antiandrogen, a type of hormonal agent. Dietary supplements, in contrast, are generally not regulated as medicines and do not require a prescription.


Q: Is Liberprost a treatment for the underlying cause, or just the symptoms?

According to official sources, the drug works by a mechanism called androgen receptor blockade. This process suppresses the hormonal signals that are necessary for cell growth and proliferation in hormone-sensitive processes.


Q: Do I need to stop taking Liberprost suddenly, or should it be a gradual process?

Regulatory information does not provide a general protocol for gradually stopping the medication. However, official label instructions specify that in cases of severe side effects, such as significant liver toxicity, the drug should be discontinued immediately under medical follow-up.


Q: What is the expected timeline for a follow-up appointment after starting Liberprost?

Regulatory guidelines emphasize the need for close monitoring during treatment, particularly with liver function tests during the first four months and periodically after that. The specific scheduling and frequency of follow-up appointments are generally determined by medical practice based on clinical assessment.


Q: Does Liberprost interact with alcohol?

Official patient information suggests that while alcohol may not affect the drug's core mechanism, it can potentially worsen common side effects, such as hot flashes and dizziness. Furthermore, combining alcohol with this medication may be associated with an increased risk of liver problems.


Q: What if I experience a rare or unexpected side effect from Liberprost?

Patients are generally advised to discuss all side effects, whether common, rare, or unexpected, with a healthcare provider. Government regulatory bodies, such as the FDA, also provide voluntary programs (like MedWatch) for patients to directly report any unexpected or serious adverse events.


Q: Are the effects of Liberprost permanent after stopping the medicine?

The official documents require males of reproductive potential to use effective contraception during and for a period after treatment cessation. This is because the medication might affect fertility, but regulatory information indicates it is not known whether this effect is permanent.


Q: Is Liberprost safe to use before driving or operating machinery?

Official warnings advise that the drug may cause sleepiness or drowsiness in some individuals. Due to this potential effect on alertness, regulatory warnings advise against driving or operating hazardous machinery until the individual understands how the medication affects them.


Q: What happens if I accidentally take more Liberprost than recommended?

Official information notes that there is currently no specific antidote available for an overdose of this medication. In such an event, treatment would be focused on managing the symptoms and providing general supportive care while closely monitoring vital signs.


Q: Is Liberprost commonly associated with weight change?

Official documents indicate that weight gain is listed as a common side effect associated with the use of this medication. Additionally, reports of unusual weight gain or loss have also been noted in the safety information.


Q: What should I do if my symptoms do not improve while using Liberprost?

Official guidelines suggest that if certain lab values, such as PSA levels, rise during therapy, the patient should be evaluated for disease progression. Concerns about symptoms or lack of improvement should always be discussed with the prescribing healthcare provider.


Q: Can I take Liberprost with caffeine?

Regulatory documents do not list caffeine as a specific drug interaction that affects the medication's core mechanism. However, caffeine is often noted in patient guidance as a common hot flash trigger that may be advised to limit, as hot flashes are a known side effect of this drug.


Q: Is Liberprost considered a standard first-line treatment for the condition it treats?

According to the official indications, the drug is utilized in different ways depending on the condition being treated. It is often used in combination with an LHRH analog for metastatic disease, and it can also be used as monotherapy for locally advanced disease, based on the approved treatment protocol for a specific region.


Q: What are the signs of an allergic reaction to Liberprost?

Official safety information states that signs of a serious allergic reaction may include skin rash, hives, itching, and swelling of the face, lips, tongue, or throat. Additionally, trouble breathing or wheezing can occur. If any of these signs appear, the protocol is to seek immediate medical attention.


How should Liberprost be stored and disposed of?

Liberprost (Bicalutamide) tablets must be stored according to strict regulatory conditions to ensure quality and prevent harm.

Storage Requirements

The medication must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be kept in the original container, which should be tightly closed and protected from moisture and direct light. The labeling explicitly requires that Liberprost be stored out of the sight and reach of children.

Prohibited Storage and Disposal

It is required to keep the tablets from freezing and away from excessive heat. Disposal must follow official guidelines; unused or expired medication should be disposed of in accordance with local requirements, typically through an authorized drug take-back program. The tablets must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Liberprost found in:

A-Z Index: